All you want to know about Cannabinoid Oil (CBD)
Updated: May 14
CBD oil is derived from the Hemp plant (Cannabis Sativa). It is a strain of the Cannabis sativa plant subspecies and consequently differs from the marijuana cannabis sativa plant (1). The hemp plant however is very low in THC (tetrahydrocannaboid) (2) that has the well known psychodelic effect but high in concentration of cannabidiol (CBD) with its multiple nourishing effects on the body.
The naturally occurring hemp plant derived cannabinoids, including the cannabidiol, share similar chemical structures as present in our body. This is why CBD interacts with our own cannabinoid system.
The WHO ( World Health Organization ) in November 2017 has issued the following statement:
“While the number of studies is limited, the evidence from well controlled human experimental research indicates that CBD is not associated with abuse potential."
Even in high doses ( 400mg ) oral intake of cannabidiol did not show in any study any change in mood change, cognitive function or motor skills (3). CBD oil that has minimal or no THC (less than 0.3%) is legal in Canada and the USA and classified a herbal product.
CBD oil has the following well established effects:
Reduction of sebum (acne)
Immune system enhancement
Consequently, CBD oil makes a perfect substance for skin health (4).
CBD oil also contains next to the cannabidiol vitamins A and E, omega3 and omega6 fatty acids and several minerals like Zn (zinc) and Mg (magnesium). This all is of additional nourishing effect for application on the skin.
Our hemp derived CBD oil is made from high CBD, low THC hemp plants which is certified by independent laboratory testing from our supplier.
It is well established that our body contains a endocannaboid system (ECS) in many organs with receptors CE1 and CE2 that have different affinity for CBD. The CE2 receptors are in the brain and central and peripheral nervous system, gastrointestinal and cardiovascular system while CE1receptors are in skin and bone. Both receptors are associated with the immune system. Physiologic processes like mood, appetite, sleep disorders and pain sensation are all part subject to our biologic regulatory system wired to keep our body in balance. That is why CBD has many positive effects including on pain sensation (2).
The medical profession is still discussing the ultimate effectiveness of CBD in general but more specifically the effect on pain which is contrary to many patients reporting relief of pain especially patients suffering from arthritis (5, 6) and many times following no or minimal relief from several pain medications (7).
In patient reports also it is remarkable that no side effects were noticed with CBD and that in sharp contrast to adverse effects of prescribed pain medications (8, 9).
Many reports are shared in the media from patients with rheumatoid arthritis, osteoarthritis, post herpetic pains, diabetic foot pain (8) and other forms of polyneuropathy. A side effect of polyneuropathy is loss of balance which leads to falls (and fractures!) as the nerve endings reduce the touch in and under the feet. Sometimes a cream with capsaicin is prescribed for polyneuropathy but is hard to tolerate as it causes burning pain and can lead to nerve damage as well thus being counter productive.
Cancer patients that experience during and even after discontinuing chemotherapy CINP (chemo induced neuropathy pain) (10, 11, 12, 13) especially with cisplatin and vincristine that have seen no effect from medications like gabapentin, tramadol or opioids have reported relief of their neuropathic pain using topical CBD. Also vit.12 was well established in trials to have no effect in reducing or preventing pain in polyneuropathy in patients on chemotherapy (14).
In a USA clinical study by D.H. Xu ea (15) the conclusion of this peer reviewed recent publication re. testing transdermal application of CBD is:
“Transdermal application of CBD oil can achieve significant improvement in pain and other disturbing sensations in patients with peripheral neuropathy. The treatment product was well tolerated and may provide a more effective alternative compared to other current therapies in the treatment of polyneuropathy.“
In another review study using clinical patient data (16) the authors concluded that:
"The evidence from current research supports the use of medical cannabis in the treatment of chronic pain in adults. Careful follow-up and monitoring of patients using cannabis/cannabinoids are mandatory."
Based upon the outcome of many clinical observational studies topical cannabidiol (CBD) has shown relief for patients suffering from different pain syndromes in the extremities like polyneuropathy and painful osteo- and rheumatoid arthritis without any adverse effect where oral pain medications have failed.
www.health.harvard.edu (search for CBD)
www.diabetes.org (all about DM and Polyneuropathy)
www.foundationforpn.org (all about Polyneuropathy)
VanDolah HJ, e.a Clinicans’ Guide to Cannabidiol and Hemp oils. Mayo Clin Proc. 2019, vol: 94 (9): 1840-1851
Capano A, e.a Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020, vol: 132 (1): 56-61
Grotenhermen F, e.a Even high doses of oral Cannabidiol do not cause THC-like effects in humans. Cannabis Cannabinoid Res. 2017, vol: 1 (2): 1-4
Sheriff T, e.a The potential role of Cannabinoids in dermatology. J Dermatolog Treat. 2019, vol: 10: 1-7
Hammell DC, e.a Transdermal cannabidiol reduces inflammation and pain-related behaviours in rat model of arthritis. Eur J Pain. 2016, vol: 20 (6): 936-48
Lowin T, e.a Joints for joints: cannabinoids in the treatment of rheumatoid arthritis. Curr opin Rheumatol. 2019, vol: 31 (3): 271-278
Pachman DR, e.a Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther. 2011, vol: 90 (3): 377-87
Bellows BK, e.a Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine. Pain. 2016, vol: 157 (1): 203-13
Grisold W, e.a Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012, vol: 14 Suppl 4: iv 45-54
O’Connor AB, e.a A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008: vol: 26 (12): 1045-64
Jordan B, e.a Prevention and Management of Chemotherapy-Induced Polyneuropathy. Breast Cancer (Basel). 2019, vol: 14 (2): 79-84
GieBen-Jung C, e.a Pheripheral neuropathy as a side effect of chemotherapy and targeted therapy. Dtsch Med Wochenschr. 2018, vol: 113 (13): 970-978
Tsurutani J, e.a Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study. Breast Cancer. 2019, vol: 26 (2): 235-243
Schloss JM, e.a A randomized, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Support Care Cancer. 2017, vol: 25 (1): 195-204
Xu DH, e.a The effectiveness of topical Cannabidiol in Symptomatic relief of Peripherl Neuropathy of the lower extremities. Curr Pharm Biotechnol. 2019, vol: 1
Vuckovic S, e.a Cannabinoids and pain : New insights from old molecules Front Pharmacol. 218, vol. 9, pg. 1259